SCHEMBL4706975

SCHEMBL4706975

CCCC[Sn](CCCC)(CCCC)c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
USP2 O75604 3/20 0.33
CYP3A4 P08684 3/20 0.33
POLB P06746 2/20 0.33
TSHR P16473 2/20 0.33
HIF1A Q16665 2/20 0.33
CDC7 O00311 1/20 0.33
CYP2D6 P10635 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPK14 Q16539 1/20 0.32
GRM2 Q14416 2/20 0.31
KIF11 P52732 1/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2B Q13224 1/20 0.31
HTT P42858 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
RIPK3 Q9Y572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638838 0.91 POLB (0.38) HSP90AA1HSP90AB1POLBGRM2HTT
SCHEMBL4759295 0.88 POLB (0.37) HSP90AA1HSP90AB1CYP3A4POLBCYP2D6
SCHEMBL4705960 0.88 HSP90AA1 (0.33) HSP90AA1HSP90AB1POLBGRIN1GRIN2B
SCHEMBL4707593 0.83 P2RX7 (0.36) HSP90AA1HSP90AB1USP2CYP3A4TSHR
SCHEMBL4708507 0.83 HSP90AA1 (0.34) HSP90AA1HSP90AB1POLBCYP2D6SMN1; SMN2
SCHEMBL3673183 0.82 CDC7 (0.48) CDC7MAPK14GRM2RIPK3
SCHEMBL4707683 0.81 HSP90AA1 (0.35) HSP90AA1HSP90AB1POLBSMN1; SMN2HTT
SCHEMBL4708592 0.78 HSP90AA1 (0.33) HSP90AA1HSP90AB1POLBAKR1C3GABRA2
SCHEMBL4708607 0.77 GABRA2 (0.35) HSP90AA1HSP90AB1GRM2GABRA2GABRB2
SCHEMBL20991111 0.76 HSP90AA1 (0.39) HSP90AA1HSP90AB1USP2CYP3A4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320994-B2 Triazole derivatives as tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1501809-B1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-01-16 EP disclosed
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists ELI LILLY COMPANY (US) 2005-10-27 US disclosed
EP-1501809-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091226-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists TACR1, TACR2, BDKRB1 HSP90AA1 2440/4885HSP90AB1 2178/4885USP2 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.